Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US
The intelligent connected bed is one of the most significant breakthroughs in India’s journey to create a world-class connected healthcare system to deliver quality healthcare to a billion Indians.
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
Company appoints five new independent directors to reconstituted board
Subscribe To Our Newsletter & Stay Updated
